Evaluation of the use of chlorpromazine for agitation in pediatric patients.

The Mental Health Clinician Pub Date : 2021-03-31 eCollection Date: 2021-03-01 DOI:10.9740/mhc.2021.03.040
Rajwoana Ahmed, Megan Maroney, Germin Fahim, Hoytin Lee Ghin, Andrew Scott Mathis
{"title":"Evaluation of the use of chlorpromazine for agitation in pediatric patients.","authors":"Rajwoana Ahmed,&nbsp;Megan Maroney,&nbsp;Germin Fahim,&nbsp;Hoytin Lee Ghin,&nbsp;Andrew Scott Mathis","doi":"10.9740/mhc.2021.03.040","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Chlorpromazine is a first-generation antipsychotic used for behavioral problems in pediatric patients. However, other therapies may demonstrate both improved outcomes and fewer side effects. Within our institution, chlorpromazine has been the standard medication used for treatment of pediatric agitation. The study objective was to evaluate the appropriateness of chlorpromazine use (including efficacy, appropriate dosing, drug interactions, and tolerability) to optimize the treatment of pediatric agitation.</p><p><strong>Methods: </strong>Data regarding drug interactions, patient behavior, dosing, and side effects was collected for each patient administered chlorpromazine from January 2019 through June 2019. Data were analyzed using descriptive statistics assessing the incidence of drug-drug interactions (DDIs), incidences of inefficacy, inappropriate dosing, and side effects.</p><p><strong>Results: </strong>A total of 70 patients and 130 administrations of oral or intramuscular chlorpromazine were evaluated. Of these administrations, 49 (38%) resulted in a DDI. Eighteen (14%) administrations were ineffective for managing symptoms of agitation. Eleven (8%) administrations were dosed inappropriately, and 46 (35%) administrations resulted in side effects possibly caused by chlorpromazine.</p><p><strong>Discussion: </strong>Results from this study demonstrate opportunities for improvement in patient care due to instances of drug interactions, inefficacy, inappropriate dosing, and side effects with the use of chlorpromazine.</p>","PeriodicalId":22710,"journal":{"name":"The Mental Health Clinician","volume":"11 2","pages":"40-44"},"PeriodicalIF":0.0000,"publicationDate":"2021-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6d/15/i2168-9709-11-2-40.PMC8019542.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Mental Health Clinician","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.9740/mhc.2021.03.040","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/3/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

Introduction: Chlorpromazine is a first-generation antipsychotic used for behavioral problems in pediatric patients. However, other therapies may demonstrate both improved outcomes and fewer side effects. Within our institution, chlorpromazine has been the standard medication used for treatment of pediatric agitation. The study objective was to evaluate the appropriateness of chlorpromazine use (including efficacy, appropriate dosing, drug interactions, and tolerability) to optimize the treatment of pediatric agitation.

Methods: Data regarding drug interactions, patient behavior, dosing, and side effects was collected for each patient administered chlorpromazine from January 2019 through June 2019. Data were analyzed using descriptive statistics assessing the incidence of drug-drug interactions (DDIs), incidences of inefficacy, inappropriate dosing, and side effects.

Results: A total of 70 patients and 130 administrations of oral or intramuscular chlorpromazine were evaluated. Of these administrations, 49 (38%) resulted in a DDI. Eighteen (14%) administrations were ineffective for managing symptoms of agitation. Eleven (8%) administrations were dosed inappropriately, and 46 (35%) administrations resulted in side effects possibly caused by chlorpromazine.

Discussion: Results from this study demonstrate opportunities for improvement in patient care due to instances of drug interactions, inefficacy, inappropriate dosing, and side effects with the use of chlorpromazine.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
氯丙嗪治疗小儿躁动的疗效评价。
氯丙嗪是第一代用于儿科患者行为问题的抗精神病药物。然而,其他疗法可能既改善了结果,又减少了副作用。在我们的机构里,氯丙嗪一直是治疗小儿躁动的标准药物。本研究的目的是评估氯丙嗪使用的适宜性(包括疗效、合适的剂量、药物相互作用和耐受性),以优化小儿躁动的治疗。方法:收集2019年1月至2019年6月服用氯丙嗪的每位患者的药物相互作用、患者行为、剂量和副作用等数据。数据分析采用描述性统计评估药物-药物相互作用(ddi)的发生率,无效的发生率,不适当的剂量和副作用。结果:共对70例患者和130次口服或肌注氯丙嗪进行了评估。在这些治疗中,49例(38%)导致DDI。18次(14%)用药对控制躁动症状无效。11例(8%)给药不当,46例(35%)给药产生可能由氯丙嗪引起的副作用。讨论:本研究的结果表明,由于氯丙嗪的药物相互作用、无效、剂量不当和副作用,患者护理有改善的机会。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Exploring real-world symptom impact and improvement in well-being domains for tardive dyskinesia in VMAT2 inhibitor-treated patients via clinician survey and chart review Impact of Board Certified Psychiatric Pharmacists on improving urinary tract infection antibiotic appropriateness at an acute psychiatric hospital Barriers to access to psychiatric medications in Missouri county jails Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports Intranasal ketamine as a treatment for psychiatric complications of long COVID: A case report
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1